Evidence of Disrupted-in Schizophrenia 1 (DISC1) as an arsenic binding protein and implications regarding its role as a translational activator.

Disrupted-in-schizophrenia-1 (DISC1) is a scaffold protein that plays a pivotal role in orchestrating signaling pathways involved in neurodevelopment, neural migration, and synaptogenesis. Among those, it has recently been reported that the role DISC1 in the Akt/mTOR pathway can shift from a global translational repressor to a translational activator in response to oxidative stress induced by arsenic. In this study we are providing evidence that DISC1 can directly bind arsenic via a C-terminal cysteine motif (C-X-C-X-C). A series of fluorescence-based binding assays were conducted with a truncated C-terminal domain construct of DISC1 and a of series of single, double, and triple cysteine mutants. We found that arsenous acid, a trivalent arsenic derivative, specifically binds to the C-terminal cysteine motif of DISC1 with low micromolar affinity. All three cysteines of the motif are required for high-affinity binding. Electron microscopy experiments combined with in silico structural predictions revealed that that the C-terminal of DISC1 forms an elongated tetrameric complex. The cysteine motif is consistently predicted to be located within a loop, fully exposed to solvent, providing a simple molecular framework to explain the high-affinity of DISC1 toward arsenous acid. This study sheds light on a novel functional facet of DISC1 as an arsenic binding protein and highlights its potential role as both a sensor and translational modulator within the Akt/mTOR pathway.

Evidence of DISC1 as an arsenic binding protein and implications regarding its role as a translational activator.

Disrupted-in-schizophrenia-1 (DISC1) is a scaffolding protein that plays a pivotal role in orchestrating signaling pathways involved in neurodevelopment, neural migration, and synaptogenesis. Among those, it has recently been reported that the role of DISC1 in the Akt/mTOR pathway can shift from a global translational repressor to a translational activator in response to oxidative stress induced by arsenic. In this study we provide evidence that DISC1 can directly bind arsenic via a C-terminal cysteine motif (C-X-C-X-C). A series of fluorescence-based binding assays were conducted with a truncated C-terminal domain construct of DISC1 and a series of single, double, and triple cysteine mutants. We found that arsenous acid, a trivalent arsenic derivative, specifically binds to the C-terminal cysteine motif of DISC1 with low micromolar affinity. All three cysteines of the motif are required for high-affinity binding. Electron microscopy experiments combined with in silico structural predictions reveal that the C-terminal of DISC1 forms an elongated tetrameric complex. The cysteine motif is consistently predicted to be located within a loop, fully exposed to solvent, providing a simple molecular framework to explain the high-affinity of DISC1 toward arsenous acid. This study sheds light on a novel functional facet of DISC1 as an arsenic binding protein and highlights its potential role as both a sensor and translational modulator within Akt/mTOR pathway.

Coupling of propylene oxide and lactide at a porphyrin chromium(III) center.

5,10,15,20-Tetraphenylporphyrin chromium chloride (TPPCrCl) with added [Ph3P═N═PPh3](+)Cl(-) (PPN(+)Cl(-)) selectively polymerizes lactide (L and rac) dissolved in neat propylene oxide (PO) to yield polylactide (PLA) terminated by the -OCHMeCH2Cl group. At 0 °C and below, rac-LA yields polymers highly enriched in isotactic tetrads (iii). At 25 °C, some stereoselectivity is lost as transesterification becomes significant, and at 60 °C and above, enchainment of PO leads to the formation of 3,6-dimethyl-1,4-dioxan-2-one by a backbiting mechanism. At 0 °C, after the enchainment of L-(S,S)-LA in neat (R)-(+)-PO, the formation of (3S,6R)-3,6-dimethyl-1,4-dioxan-2-one occurs, while at higher temperatures the ratio of (3S,6R)-3,6-dimethyl-1,4-dioxan-2-one to (3R,6R)-3,6-dimethyl-1,4-dioxan-2-one falls to 3:2.

NIH Current Clinical Research Studies

It allows access to a database on clinical trials conducted at the NIH Warren Grant Magnuson Clinical Center. The user can enter the diagnosis, sign, symptom, or other key words or phrases, to search the full-text records (including or excluding the eligibility criteria).